The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

The ERS/ESTS guidelines also state that the first estimate of residual lung function should be calculated based on segment counting. Only segments not totally obstructed should be taken into ...

28, 2025 (GLOBE NEWSWIRE) -- Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight The pulmonary ...

Increase in incidences of cancer worldwide and favorable reimbursement policies provided by manufacturers & insurance providers drive the growth of the market ...